P
Pingda Ren
Researcher at University of Michigan
Publications - 78
Citations - 5332
Pingda Ren is an academic researcher from University of Michigan. The author has contributed to research in topics: PI3K/AKT/mTOR pathway & Kinase. The author has an hindex of 25, co-authored 76 publications receiving 4529 citations. Previous affiliations of Pingda Ren include University of California & Torrey Pines Institute for Molecular Studies.
Papers
More filters
Journal ArticleDOI
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Andrew C. Hsieh,Yi Liu,Merritt Edlind,Nicholas T. Ingolia,Matthew R. Janes,Annie Sher,Evan Y. Shi,Craig R. Stumpf,Carly Christensen,Michael Bonham,Shunyou Wang,Pingda Ren,Michael C. Martin,Katti Jessen,Morris E. Feldman,Jonathan S. Weissman,Kevan M. Shokat,Christian Rommel,Davide Ruggero +18 more
TL;DR: A clinically relevant ATP site inhibitor of mTOR, INK128, is developed, which reprograms this gene expression signature with therapeutic benefit for prostate cancer metastasis, for which there is presently no cure.
Journal ArticleDOI
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Matthew R. Janes,Jingchuan Zhang,Lian-Sheng Li,Rasmus Hansen,Ulf Peters,Xin Guo,Yuching Chen,Anjali Babbar,Sarah J. Firdaus,Levan Darjania,Jun Feng,Jeffrey H. Chen,Shuangwei Li,Shisheng Li,Yun O. Long,Carol Thach,Yuan Liu,Ata Zarieh,Tess Ely,Jeff Kucharski,Linda Kessler,Tao Wu,Ke Yu,Yi Wang,Yvonne Yao,Xiaohu Deng,Patrick P. Zarrinkar,Dirk Brehmer,Dashyant Dhanak,Matthew V. Lorenzi,Dana D. Hu-Lowe,Matthew P. Patricelli,Pingda Ren,Yi Liu +33 more
TL;DR: This study provides in vivo evidence that mutant KRAS can be selectively targeted and reveals ARS-1620 as representing a new generation of KRASG12C-specific inhibitors with promising therapeutic potential.
Journal ArticleDOI
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Matthew P. Patricelli,Matthew R. Janes,Lian-Sheng Li,Rasmus Hansen,Ulf Peters,Linda Kessler,Yuching Chen,Jeff Kucharski,Jun Feng,Tess Ely,Jeffrey H. Chen,Sarah J. Firdaus,Anjali Babbar,Pingda Ren,Yi Liu +14 more
TL;DR: ARS-853 is described, a selective, covalent inhibitor of KRAS(G12C) that inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation.
Journal ArticleDOI
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
Matthew R. Janes,Jose J. Limon,Lomon So,Jing Chen,Raymond J Lim,Melissa A Chavez,Collin Vu,Michael B. Lilly,Sharmila Mallya,S. Tiong Ong,Marina Konopleva,Michael B. Martin,Pingda Ren,Yi Liu,Christian Rommel,David A. Fruman +15 more
TL;DR: It is established that Ph+ transformed cells are more sensitive than normal lymphocytes to selective TORC1/2 inhibitors and support the development of such inhibitors for leukemia therapy.
Patent
Heterocyclic compounds and uses thereof
Alfredo C. Castro,Catherine A. Evans,Somarajannair Janardanannair,Andre Lescarbeau,Tao Liu,Daniel A. Snyder,Martin R. Tremblay,Pingda Ren,Yi Liu,Liansheng Li,Katrina Chan +10 more
TL;DR: In this article, compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activation, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activations are described.